Information Provided By: 
Fly News Breaks for December 6, 2016
AGIO
Dec 6, 2016 | 09:17 EDT
Needham analyst Chad Messer said the pullback in Agios Pharmaceuticals shares following ASH is a buying opportunity. He said shares traded down 13% yesterday over safety concerns from a single patient with cholestatic hepatitis on AG-519, which occurred at 6x+ the likely go forward does. Further, concerns over perceived efficacy drop-off for AG-348 is misguided in light of additional data presented on response by genotype, the analyst wrote. Messer rates Agios a Buy with a $60 price target.
News For AGIO From the Last 2 Days
There are no results for your query AGIO
